e-Therapeutics’ new boss sees lots of potential

  • E-therapeutics appoints head of intellectual property
  • e-Therapeutics reveals results from compound tests for potential coronavirus treatment
scientist in a lab

Quick facts: e-Therapeutics PLC


View company profile

e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity.

The company combines network science, machine learning, artificial intelligence, statistics and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.

02 Jun 2021

Drug discovery group E-therapeutics PLC () appointed Alison Gallafent as its head of intellectual property.

A UK-chartered patent attorney and European patent attorney, she brings 20-years experience to the role having worked at Merck & Co, Glaxo Wellcome, PLIVA and, more recently, in a similar role at Silence Therapeutics.

E-therapeutics’ chief executive, Ali Mortazavi, said: “We are delighted to welcome Alison to e- therapeutics at this point in the company’s evolution. The combination of her broad industry and RNAi expertise will be a major addition to the team.”

In the same announcement, investors were told options over 500,000 and 1.25mln shares were granted respectively to Alison Gallafent and Karl Keegan, chief financial officer, who joined the company in March.

Read more

14 May 2021

e-Therapeutics PLC () raised GBP22.5mln in an equity funding, comprising a placing and a retail offer.

The company initially announced a GBP20mln funding after market close on Thursday then this morning confirmed it had raised additional funds.

Read more

13 May 2021

E-therapeutics PLC () said forming partnerships and deals will be key priorities for the coming year, including for its new RNA interference (RNAi) platform as this is an area currently commanding significant and attractive deals.

The past year, while challenging, has opened up new opportunities for the computational drug discovery company, with the expansion into RNAi as a therapeutic modality, the formation of a new collaboration with Belgian life sciences company Galapagos, extension of a partnership with Danish giant and the initiation of a project to identify approved and known drugs that could rapidly be repositioned for the treatment of COVID-19.

Read more

09 Dec 2020

e-Therapeutics PLC’s () Alan Whitmore joins Proactive London’s Katie Pilbeam to explain the results of experimental testing on compounds for the treatment of coronavirus (COVID-19), identified using its Network-driven Drug Discovery (NDD) platform.

Whitmore explains that when they analysed the latest data, the systemic inflammatory response syndrome and of data sets from human cells infected with SARS-CoV-2, the virus that causes COVID-19, there was an overlap important to both the virus and the hyperinflammatory response.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


Market Report: FTSE follows Wall Street rally after global sell off

FTSE 100 wiped out some of Thursday’s losses at open after a rally on Wall Street, with traders awaiting US retail sales data later today. London’s leading index jumped 41 points to 7,005 in early trading.

Airbnb Inc (NASDAQ:ABNB) has seen an increase in bookings in countries where the…

2 weeks, 5 days ago

2 min read


Please enter your comment!
Please enter your name here